Status:
UNKNOWN
Sulforaphane Supplementation Study
Lead Sponsor:
University of Oxford
Collaborating Sponsors:
Quadram Institute Bioscience
Conditions:
Non-Alcoholic Fatty Liver Disease
Obesity
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Non-alcoholic fatty liver disease (NAFLD) is increasing in the population, and is associated with heart disease and diabetes. At present there are no licensed drugs for treatment of NAFLD, therefore c...
Detailed Description
Participants satisfying the inclusion criteria will be invited to the Oxford Centre for Clinical Magnetic Resonance Research (OCMR), to measure the amount of fat within their liver and heart using mag...
Eligibility Criteria
Inclusion
- Participant is willing and able to give informed consent for participation in the study.
- Healthy adults, Male or Female, aged 18 to 65 years.
- No medical condition or relevant drug therapy known to affect glucose or fatty acid metabolism.
- Weight stable for the previous 3 months. -
Exclusion
- Aged ≤18 or ≥65 years.
- Body Mass Index ≤19 or ≥35kg/m2.
- Females with a body mass ≤50kg.
- A blood haemoglobin \<135mg/dL for men and \<120mg/dL for women.
- Donated (or lost) ≥250 ml of blood in the previous two months.
- On a weight loss diet or have decreased their body weight by \>5% in the previous 3 months.
- Have increased their body weight by \>5% in the previous 3 months.
- Any metabolic condition or relevant drug therapy known to affect glucose or fatty acid metabolism.
- Smoking, or use of nicotine replacement agents (e.g. e-cigarettes).
- History of alcoholism or a greater than recommended alcohol intake (\>30 g of alcohol daily for men and \>20 g of alcohol daily for women).
- Current or history of Haemorrhagic disorders.
- History of albumin allergy or allergic to eggs
- Current or history of anticoagulant treatment.
- Pregnant or nursing mothers.
- Women prescribed any hormone replacement therapy (HRT) or who have used these within the last 12 months.
- History of severe claustrophobia.
- Presence of metallic implants, pacemaker, or inability/unwillingness to remove any piercings, and any large tattoos around the area to be scanned.
- History or current psychiatric illness.
- History or current neurological condition (e.g. epilepsy).
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04364360
Start Date
January 1 2020
End Date
August 1 2023
Last Update
June 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oxford Centre for Diabetes, Endocrinology and Metabolism
Oxford, Oxfordshire, United Kingdom, OX3 7LE